PT1660090E - Análogos de quinazolina como inibidores de tirosina-cinases recetoras - Google Patents

Análogos de quinazolina como inibidores de tirosina-cinases recetoras

Info

Publication number
PT1660090E
PT1660090E PT47809900T PT04780990T PT1660090E PT 1660090 E PT1660090 E PT 1660090E PT 47809900 T PT47809900 T PT 47809900T PT 04780990 T PT04780990 T PT 04780990T PT 1660090 E PT1660090 E PT 1660090E
Authority
PT
Portugal
Prior art keywords
tyrosine kinase
kinase inhibitors
receptor tyrosine
quinazoline analogs
quinazoline
Prior art date
Application number
PT47809900T
Other languages
English (en)
Inventor
Qian Zhao
Eli Wallace
George Topalov
Joseph Lyssikatos
Alexandre Buckmelter
Original Assignee
Array Biopharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US10/642,440 external-priority patent/US7501427B2/en
Application filed by Array Biopharma Inc filed Critical Array Biopharma Inc
Publication of PT1660090E publication Critical patent/PT1660090E/pt

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72Quinazolines; Hydrogenated quinazolines
    • C07D239/86Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C07D239/94Nitrogen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C04CEMENTS; CONCRETE; ARTIFICIAL STONE; CERAMICS; REFRACTORIES
    • C04BLIME, MAGNESIA; SLAG; CEMENTS; COMPOSITIONS THEREOF, e.g. MORTARS, CONCRETE OR LIKE BUILDING MATERIALS; ARTIFICIAL STONE; CERAMICS; REFRACTORIES; TREATMENT OF NATURAL STONE
    • C04B35/00Shaped ceramic products characterised by their composition; Ceramics compositions; Processing powders of inorganic compounds preparatory to the manufacturing of ceramic products
    • C04B35/622Forming processes; Processing powders of inorganic compounds preparatory to the manufacturing of ceramic products
    • C04B35/626Preparing or treating the powders individually or as batches ; preparing or treating macroscopic reinforcing agents for ceramic products, e.g. fibres; mechanical aspects section B
    • C04B35/63Preparing or treating the powders individually or as batches ; preparing or treating macroscopic reinforcing agents for ceramic products, e.g. fibres; mechanical aspects section B using additives specially adapted for forming the products, e.g.. binder binders
    • C04B35/632Organic additives
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D498/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D498/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/10Spiro-condensed systems
PT47809900T 2003-08-14 2004-08-10 Análogos de quinazolina como inibidores de tirosina-cinases recetoras PT1660090E (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10/642,440 US7501427B2 (en) 2003-08-14 2003-08-14 Quinazoline analogs as receptor tyrosine kinase inhibitors
US55171804P 2004-03-10 2004-03-10

Publications (1)

Publication Number Publication Date
PT1660090E true PT1660090E (pt) 2013-01-11

Family

ID=34198338

Family Applications (1)

Application Number Title Priority Date Filing Date
PT47809900T PT1660090E (pt) 2003-08-14 2004-08-10 Análogos de quinazolina como inibidores de tirosina-cinases recetoras

Country Status (24)

Country Link
US (2) US7452895B2 (pt)
EP (1) EP1660090B1 (pt)
JP (1) JP4828421B2 (pt)
KR (2) KR101028952B1 (pt)
CN (3) CN103664802B (pt)
AR (1) AR045378A1 (pt)
AU (1) AU2004264937B2 (pt)
BR (1) BRPI0413565B8 (pt)
CA (1) CA2535614C (pt)
CL (1) CL2004002066A1 (pt)
CY (1) CY1113992T1 (pt)
DK (1) DK1660090T3 (pt)
ES (1) ES2399427T3 (pt)
HK (1) HK1085400A1 (pt)
IL (1) IL173593A (pt)
IS (1) IS8288A (pt)
MX (1) MXPA06001767A (pt)
NO (1) NO336275B1 (pt)
NZ (1) NZ545459A (pt)
PL (1) PL1660090T3 (pt)
PT (1) PT1660090E (pt)
RU (1) RU2350605C2 (pt)
TW (1) TWI353982B (pt)
WO (1) WO2005016346A1 (pt)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7488823B2 (en) * 2003-11-10 2009-02-10 Array Biopharma, Inc. Cyanoguanidines and cyanoamidines as ErbB2 and EGFR inhibitors
CN103664802B (zh) * 2003-08-14 2015-08-05 阿雷生物药品公司 作为受体酪氨酸激酶抑制剂的喹唑啉类似物
US7501427B2 (en) 2003-08-14 2009-03-10 Array Biopharma, Inc. Quinazoline analogs as receptor tyrosine kinase inhibitors
ES2335535T3 (es) * 2005-11-15 2010-03-29 Array Biopharma Inc. Derivados de n4-fenil-quinazolin-4-amina ycompuestos afines como inhibidores de la tirosina quinasa receptora erbb tipo i para el tratamiento de enfermedades hiperproliferativas.
CN104011047A (zh) 2011-10-14 2014-08-27 阵列生物制药公司 选择性herb2抑制剂arry-380的多晶型物和含有它们的药物组合物
HUE035247T2 (hu) 2011-10-14 2018-05-02 Array Biopharma Inc Szilárd diszperzió
JP2015514075A (ja) 2012-03-23 2015-05-18 アレイ バイオファーマ、インコーポレイテッド 脳癌の治療
JP2018535923A (ja) * 2015-09-04 2018-12-06 アスラン ファーマシューティカルズ ピーティーイー リミテッド 胆道癌の治療
US20190134034A1 (en) * 2016-04-21 2019-05-09 Aslan Pharmaceuticals Pte. Ltd. Method of Treating Liver Cancer
GB201611580D0 (en) * 2016-07-01 2016-08-17 Aslan Pharmaceuticals Pte Ltd Method
CN106317040A (zh) * 2016-08-09 2017-01-11 浙江医药高等专科学校 含噻吩磺酰胺结构的苯并喹唑啉类酪氨酸激酶抑制剂、制备方法及用途
CN106349230A (zh) * 2016-08-09 2017-01-25 浙江医药高等专科学校 一种含硝基噻吩磺酰胺结构的苯并喹唑啉类酪氨酸激酶抑制剂及用途
CN106349231A (zh) * 2016-08-09 2017-01-25 浙江医药高等专科学校 一类含卤代噻吩磺酰胺结构的苯并喹唑啉类酪氨酸激酶抑制剂
CN106317039A (zh) * 2016-08-09 2017-01-11 浙江医药高等专科学校 一种含噻吩磺酰胺结构的乙氧苯并喹唑啉类酪氨酸激酶抑制剂、制备方法及用途
CN106279135A (zh) * 2016-08-09 2017-01-04 浙江医药高等专科学校 一种噻吩磺酰胺结构的苯并喹唑啉类酪氨酸激酶抑制剂
SG10201913858WA (en) 2016-08-26 2020-03-30 Agency Science Tech & Res Macrophage stimulating protein receptor (or ron - recepteur d' origine nantais) antibodies and uses thereof
EP3589286B1 (en) 2017-03-02 2022-08-03 ASLAN Pharmaceuticals Pte Ltd Dhodh inhibitor for treating haematological cancer
EP3615067A1 (en) 2017-04-28 2020-03-04 Seattle Genetics, Inc. Treatment of her2 positive cancers
WO2018222135A1 (en) 2017-06-02 2018-12-06 Aslan Pharmaceuticals Pte Ltd Cancer therapy
WO2018222134A1 (en) 2017-06-02 2018-12-06 Aslan Pharmaceuticals Pte Ltd Cancer therapy
PT3853220T (pt) 2018-09-18 2024-02-22 Hoffmann La Roche Derivados de quinazolina enquanto agentes antitumorais
CN112969699A (zh) * 2018-10-09 2021-06-15 亚狮康私人有限公司 瓦利替尼的丙二酸盐
CN111499622B (zh) * 2019-07-08 2023-06-06 山东省科学院菏泽分院 一种治疗胆管癌的药物的制备方法
TW202214641A (zh) 2020-06-30 2022-04-16 美商艾瑞生藥股份有限公司 Her2突變抑制劑
TW202345816A (zh) * 2022-03-28 2023-12-01 大陸商江蘇恆瑞醫藥股份有限公司 含氮雜環類化合物、其製備方法及其在醫藥上的應用

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2583774A (en) 1948-04-30 1952-01-29 Merck & Co Inc Vitamin b6 derivatives
BE795970A (fr) 1972-02-29 1973-08-27 Pfizer Nouveaux derives de quinoleine, quinoxaline et quinazoline er composition pharmaceutiques les contenant
US5204348A (en) * 1988-10-06 1993-04-20 Mitsui Toatsu Chemicals Inc. Heterocyclic compounds and anticancer-drug potentiaters conaining them as effective components
CA1340821C (en) 1988-10-06 1999-11-16 Nobuyuki Fukazawa Heterocyclic compounds and anticancer-drug reinforcing agents containing them as effective components
US5502187A (en) 1992-04-03 1996-03-26 The Upjohn Company Pharmaceutically active bicyclic-heterocyclic amines
GB9510757D0 (en) 1994-09-19 1995-07-19 Wellcome Found Therapeuticaly active compounds
TW321649B (pt) 1994-11-12 1997-12-01 Zeneca Ltd
GB9424233D0 (en) 1994-11-30 1995-01-18 Zeneca Ltd Quinazoline derivatives
AR004010A1 (es) 1995-10-11 1998-09-30 Glaxo Group Ltd Compuestos heterociclicos
KR19990082463A (ko) 1996-02-13 1999-11-25 돈 리사 로얄 혈관 내피 성장 인자 억제제로서의 퀴나졸린유도체
GB9603095D0 (en) * 1996-02-14 1996-04-10 Zeneca Ltd Quinazoline derivatives
NZ332119A (en) 1996-04-12 2001-08-31 Warner Lambert Co Quinazoline compounds which are irreversible inhibitors of tyrosine kinases
PT912559E (pt) 1996-07-13 2003-03-31 Glaxo Group Ltd Compostos heterociclicos fundidos como inibidores de proteina tirosina quinase
US6225318B1 (en) 1996-10-17 2001-05-01 Pfizer Inc 4-aminoquinazolone derivatives
ZA986732B (en) * 1997-07-29 1999-02-02 Warner Lambert Co Irreversible inhibitiors of tyrosine kinases
TW436485B (en) 1997-08-01 2001-05-28 American Cyanamid Co Substituted quinazoline derivatives
CZ20001709A3 (cs) 1997-11-11 2001-12-12 Pfizer Products Inc. Deriváty thienopyrimidu a thienopyridinu, farmaceutické kompozice a způsoby léčení na jejich bázi
JP2002505288A (ja) 1998-03-02 2002-02-19 コセンシス,インコーポレイテッド 置換キナゾリンおよびアナログならびにそれらの使用
US6017922A (en) 1998-05-18 2000-01-25 U.S. Bioscience, Inc. Thermally stable trimetrexates and processes for producing the same
EA003786B1 (ru) 1998-11-19 2003-10-30 Варнер Ламберт Компани N-[4-(3-хлор-4-фторфениламино)-7-(3-морфолин-4-илпропокси)хиназолин-6-ил]акриламид - необратимый ингибитор тирозинкиназ
GEP20032922B (en) 1999-01-13 2003-03-25 Warner Lambert Co Benzoheterocycles and Their Use as MEK Inhibitors
EP1154774B1 (en) * 1999-02-10 2005-06-22 AstraZeneca AB Quinazoline derivatives as angiogenesis inhibitors
GB9922171D0 (en) * 1999-09-21 1999-11-17 Zeneca Ltd Chemical compounds
KR20020032608A (ko) 1999-09-21 2002-05-03 다비드 에 질레스 퀴나졸린 화합물 및 이를 함유하는 제약 조성물
AU3092901A (en) 2000-02-17 2001-08-27 Bristol Myers Squibb Co Aniline-derived ligands for the thyroid receptor
TR200402656T4 (tr) 2000-06-06 2004-11-22 Pfizer Products Inc. Antikanser ajanları olarak faydalı tiyofen türevleri
MXPA02012870A (es) * 2000-06-22 2003-05-14 Pfizer Prod Inc Derivados biciclicos sustituidos para el tratamiento del crecimiento celular anormal.
CZ299561B6 (cs) * 2000-06-30 2008-09-03 Glaxo Group Limited Chinazolinaminový derivát a farmaceutický prostredek
US7265134B2 (en) 2001-08-17 2007-09-04 Merck & Co., Inc. Tyrosine kinase inhibitors
US7169788B2 (en) 2001-10-30 2007-01-30 Merck & Co., Inc. Tyrosine kinase inhibitors
CA2465068A1 (en) * 2001-11-03 2003-05-15 Astrazeneca Ab Quinazoline derivatives as antitumor agents
PT1463506E (pt) * 2001-12-24 2009-12-10 Astrazeneca Ab Derivados de quinazolina substituídos como inibidores de aurora cinases
US7488823B2 (en) 2003-11-10 2009-02-10 Array Biopharma, Inc. Cyanoguanidines and cyanoamidines as ErbB2 and EGFR inhibitors
CA2514479A1 (en) 2003-01-23 2004-08-05 T.K. Signal Ltd. Irreversible inhibitors of egf receptor tyrosine kinases and uses thereof
PE20040945A1 (es) 2003-02-05 2004-12-14 Warner Lambert Co Preparacion de quinazolinas substituidas
CA2527017A1 (en) 2003-05-27 2004-12-09 Pfizer Products Inc. Quinazolines and pyrido [3,4-d] pyrimidines as receptor tyrosine kinase inhibitors
US7501427B2 (en) * 2003-08-14 2009-03-10 Array Biopharma, Inc. Quinazoline analogs as receptor tyrosine kinase inhibitors
CN103664802B (zh) 2003-08-14 2015-08-05 阿雷生物药品公司 作为受体酪氨酸激酶抑制剂的喹唑啉类似物
EP1658080A1 (en) 2003-08-18 2006-05-24 Pfizer Products Inc. Dosing schedule for a erbb2 anticancer agents
MXPA06005024A (es) 2003-11-06 2006-07-06 Pfizer Prod Inc Combinaciones de inhibidor de erbb2 selectivo/anticuerpos anti-erbb en el tratamiento del cancer.
KR100735639B1 (ko) 2004-12-29 2007-07-04 한미약품 주식회사 암세포 성장 억제 효과를 갖는 퀴나졸린 유도체 및 이의제조방법
ES2335535T3 (es) 2005-11-15 2010-03-29 Array Biopharma Inc. Derivados de n4-fenil-quinazolin-4-amina ycompuestos afines como inhibidores de la tirosina quinasa receptora erbb tipo i para el tratamiento de enfermedades hiperproliferativas.

Also Published As

Publication number Publication date
RU2350605C2 (ru) 2009-03-27
CN103664802B (zh) 2015-08-05
CN102432552A (zh) 2012-05-02
KR20100018079A (ko) 2010-02-16
AU2004264937A1 (en) 2005-02-24
CA2535614C (en) 2009-12-22
IL173593A0 (en) 2006-07-05
JP4828421B2 (ja) 2011-11-30
DK1660090T3 (da) 2012-12-17
TW200519096A (en) 2005-06-16
US7452895B2 (en) 2008-11-18
RU2006103493A (ru) 2007-09-20
BRPI0413565B1 (pt) 2019-10-01
US8278314B2 (en) 2012-10-02
IS8288A (is) 2006-02-07
KR101028952B1 (ko) 2011-04-12
AU2004264937B2 (en) 2010-04-29
CN103664802A (zh) 2014-03-26
PL1660090T3 (pl) 2013-04-30
TWI353982B (en) 2011-12-11
ES2399427T3 (es) 2013-04-01
HK1085400A1 (en) 2006-08-25
CN103772373B (zh) 2017-06-09
BRPI0413565A (pt) 2006-10-17
NZ545459A (en) 2009-12-24
CN103772373A (zh) 2014-05-07
KR100953246B1 (ko) 2010-04-16
NO336275B1 (no) 2015-07-06
KR20060064630A (ko) 2006-06-13
CY1113992T1 (el) 2016-07-27
NO20061171L (no) 2006-04-10
IL173593A (en) 2011-11-30
JP2007502295A (ja) 2007-02-08
US20090048279A1 (en) 2009-02-19
CL2004002066A1 (es) 2005-06-03
CN102432552B (zh) 2016-01-20
EP1660090A1 (en) 2006-05-31
US20050043334A1 (en) 2005-02-24
EP1660090B1 (en) 2012-11-21
WO2005016346A1 (en) 2005-02-24
AR045378A1 (es) 2005-10-26
MXPA06001767A (es) 2006-05-12
CA2535614A1 (en) 2005-02-24
EP1660090A4 (en) 2008-12-03
BRPI0413565B8 (pt) 2021-05-25

Similar Documents

Publication Publication Date Title
HK1085400A1 (en) Quinazoline analogs as receptor tyrosine kinase inhibitors
IL174258A0 (en) Quinazoline derivatives as tyrosine kinase inhibitors
IL174261A0 (en) Quinazoline derivatives as tyrosine kinase inhibitors
IL173200A0 (en) Piperidyl-quinazoline derivatives as tyrosine kinase inhibitors
ZA200609427B (en) Quinazoline derivatives as erbB receptor tyrosine kinases
AU2003299651A8 (en) Tyrosine kinase inhibitors
EP1581539A4 (en) NEW TYROSINE KINASE HEMMER
ZA200606152B (en) 2-(3-substituted-aryl)amino-4-aryl-thiazoles as tyrosine kinase inhibitors
IL180806A0 (en) Imidazopyrazine as tyrosine kinase inhibitors
AU2003298942A8 (en) Tyrosine kinase inhibitors
IL174948A0 (en) Imidazopyrazine tyrosine kinase inhibitors
EP1656378A4 (en) COMPOUNDS AND COMPOSITIONS INHIBITING TYROSINE KINASE RECEPTOR ACTIVITY
EP1534268A4 (en) TYROSINE KINASE INHIBITORS
AU2003275282A8 (en) Novel tyrosine kinase inhibitors
HK1079195A1 (en) Quinazoline derivatives as src tyrosine kinase inhibitors
IL187895A0 (en) Benzocycloheptapyridines as inhibitors of the receptor tyrosine kinase met
IL173483A0 (en) Quinazoline derivatives as inhibitors of vegf receptor tyrosine kinases
EP1651599A4 (en) TYROSINE KINASE INHIBITORS
SI1660090T1 (sl) Kinazolinski analogi kot inhibitorji receptorjev tirozin kinaze
EP1496897A4 (en) INHIBITORS OF TYROSINE KINASES
IL184798A0 (en) Quinazoline derivatives as tyrosine kinase inhibitors
HK1120793A1 (en) 4- (ih-indazol-5-yl-amino)-quinazoline compounds as erbb receptor tyrosine kinase inhibitors for the treatment of cancer
ZA200608998B (en) Imidazole derivatives as tyrosine kinase inhibitors
EP1951252A4 (en) INHIBITORS OF TYROSINE KINASES
EP1651209A4 (en) TYROSINE KINASE INHIBITORS